SRR6013499
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.590
- MTORC1_SIGNALING+0.550
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.550
- OXIDATIVE_PHOSPHORYLATION+0.520
- ALLOGRAFT_REJECTION+0.510
- E2F_TARGETS+0.510
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.450
- GLYCOLYSIS+0.440
Top 10 suppressed
- UV_RESPONSE_DN-0.300
- NOTCH_SIGNALING-0.260
- HEDGEHOG_SIGNALING-0.250
- WNT_BETA_CATENIN_SIGNALING-0.250
- KRAS_SIGNALING_DN-0.230
- MYOGENESIS-0.080
- PANCREAS_BETA_CELLS-0.040
- SPERMATOGENESIS-0.040
- BILE_ACID_METABOLISM+0.070
- TGF_BETA_SIGNALING+0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013500 | — | cohortA1 | 0.995 |
| 2 | 27875588-7C41-49BB-A4C0-A66D72A12499 | — | — | 0.928 |
| 3 | SRR8942975 | — | — | 0.925 |
| 4 | SRR6013600 | — | cohortA1 | 0.919 |
| 5 | B9535625-504A-4FCD-B341-2985AE72508A | — | — | 0.912 |
| 6 | MDT-AP-0368 | Med | Medulloblastoma | 0.910 |
| 7 | D06FFD0C-80D4-413D-9C83-62D9C163EDAB | — | — | 0.909 |
| 8 | SRR10900566 | — | — | 0.907 |
| 9 | X16125ffc.4138.408e.9573.cd6c960504cf | — | cohortA1 | 0.902 |
| 10 | TCGA-60-2696-01A-01R-0851-07 | — | cohortSQ1 | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.590 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.550 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.550 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.410 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.340 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.340 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.330 | Inavolisib | — uncovered |